Abstract:In this study, the natural molecular history of matched primary and recurrent tumors of 19 patients with IDH‐mutant, 1p19q non‐codeleted astrocytomas without pressure of temozolomide or radiotherapy was studied. Samples were examined for DNA methylation profiling and copy number variations, gene mutations and ALT. Recurrences were characterized by new CNVs not present in the primary tumors. Few novel mutations were identified in recurrences. CDKN2A homozygous deletion, MYC or PDGFRA focal and non‐focal gain were found at recurrences. Our findings improve the understanding of the molecular life history of IDH‐mutant astrocytomas. Hypermutation and malignant transformation are potential complications arising from temozolomide treatment of IDH‐mutant gliomas. However, the natural history of IDH‐mutant low‐grade gliomas without temozolomide treatment is actually under‐studied. We retrieved retrospectively from our hospitals paired tumors from 19 patients with IDH‐mutant, 1p19q non‐codeleted Grade 2 astrocytomas where no interim adjuvant treatment with either temozolomide or radiotherapy was given between primary resections and first recurrences. Tissues from multiple recurrences were available from two patients and radiotherapy but not temozolomide was given before the last specimens were resected. We studied the natural molecular history of these low‐grade IDH‐mutant astrocytomas without pressure of temozolomide with DNA methylation profiling and copy number variation (CNV) analyses, targeted DNA sequencing, TERTp sequencing, FISH for ALT and selected biomarkers. Recurrences were mostly higher grades (15/19 patients) and characterized by new CNVs not present in the primary tumors (17/19 cases). Few novel mutations were identified in recurrences. Tumors from 17/19 (89.5%) patients showed either CDKN2A homozygous deletion, MYC or PDGFRA focal and non‐focal gains at recurrences. There was no case of hypermutation. Phylogenetic trees constructed for tumors for the two patients with multiple recurrences suggested a lack of subclone development in their evolution when under no pressure from temozolomide. In summary, our studies demonstrated, in contrast to the phenomenon of temozolomide‐induced hypermutation, IDH‐mutant, 1p19q non‐codeleted Grade 2 astrocytomas which had not been treated by temozolomide, acquired new CNVs at tumor recurrences. These findings improve our understanding of the molecular life history of IDH‐mutant astrocytomas.

IDH mutation status and the development of venous thromboembolism in astrocytoma patients

NCMP-10. IDH MUTATION STATUS AND THE DEVELOPMENT OF VENOUS THROMBOEMBOLISM IN ASTROCYTOMA PATIENTS

Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: a Retrospective Cohort Study and Meta-Analysis.

[Relationship between clinical characteristics and myelodysplastic syndrome patients with isocitrate dehydrogenase gene mutations].

Path-16. Molecular Alterations In Idh-Mutant Astrocytoma: A Multi-Institutional Retrospective Study

Combined analysis of clinical and laboratory markers to predict the risk of venous thromboembolism in patients with IDH1 wild-type glioblastoma

Dissecting the prognostic signature of patients with astrocytoma isocitrate dehydrogenase-mutant grade 4: a large multicenter, retrospective study

Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma

Venous Thromboembolism (VTE) and Glioblastoma.

A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial design

Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas

Path-44. Clinical And Radiographic Predictors Of Prognosis In Astrocytoma, Idh-Mutant, Who Grade 4

Exth-30. Genetic Alterations That Deregulate Rb And Pdgfra Signaling Pathways Drive Tumor Progression In Idh2-Mutant Astrocytoma

Anatomical and subcortical invasiveness in diffuse low-grade astrocytomas differ between IDH status and provide prognostic information

IDH1 mutations inhibit multiple α-ketoglutarate-dependent dioxygenase activities in astroglioma

Isocitrate Dehydrogenase 1/2 Wildtype Adult Astrocytoma with WHO Grade 2/3 Histological Features: Molecular Re-Classification, Prognostic Factors, Clinical Outcomes

Idh1 Mutations Inhibit Multiple Alpha-Ketoglutarate-Dependent Dioxygenase Activities In Astroglioma

Can diffusion tensor imaging noninvasively detect IDH1 gene mutations in astrogliomas? A retrospective study of 112 cases.

The molecular history of IDH‐mutant astrocytomas without adjuvant treatment

Innv-37. Real-World Outcomes Among High Grade Idh1-Mutant Glioma Patients Treated With An Idh Inhibitor

Path-12. Clinical And Neuropathological Markers For Distinguishing Between Idh-Mutant Astrocytomas Of Who Grade 2 And 3